Tempus Acquires Paige.AI in $81.2 Million Deal
PorAinvest
viernes, 22 de agosto de 2025, 2:24 pm ET1 min de lectura
TEM--
Paige.AI is an AI company specializing in digital pathology, with a strong foundation rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated [3]. The acquisition will allow Tempus to expand its dataset, enhance its technical team, and establish a robust presence in digital pathology with an industry-leading technology portfolio [3].
Tempus AI, Inc. is a technology company that leverages artificial intelligence to advance precision medicine. With one of the world's largest libraries of multimodal data and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians, facilitating personalized patient care and advancing drug discovery and development [3].
The acquisition of Paige.AI is expected to accelerate Tempus' efforts in building a large foundation model in oncology, leveraging Paige's de-identified data and AI applications to enhance Tempus' existing products [3]. Tempus' CEO, Eric Lefkofsky, stated that the acquisition of Paige will be catalytic across all of Tempus' AI efforts [3].
Razik Yousfi, CEO and CTO of Paige, expressed confidence in the partnership, stating that the combined forces of Tempus and Paige are uniquely positioned to maximize and expand the reach of their technology, ensuring it fulfills their mission of delivering powerful, data-driven insights [3].
Tempus AI's stock has seen a 2% increase following the announcement of the acquisition [2]. The stock's performance and the acquisition's impact on Tempus' financials will be closely monitored by investors and financial professionals.
References:
[1] https://www.marketscreener.com/news/tempus-ai-inc-acquired-paige-ai-inc-in-a-transaction-valued-at-81-2-million-ce7c50dbd88df121
[2] https://seekingalpha.com/news/4488345-tempus-ai-will-acquire-paige-for-8125m
[3] https://www.businesswire.com/news/home/20250822422844/en/Tempus-Announces-the-Acquisition-of-Paige
Tempus AI acquired Paige.AI for $81.2 million, paying predominantly in Tempus common stock and assuming Paige's remaining commitment under its Microsoft Azure cloud services agreement. The acquisition was completed on August 22, 2025.
Tempus AI, Inc. (NasdaqGS:TEM) has acquired Paige.AI, Inc. in a deal valued at $81.2 million, which was completed on August 22, 2025. The consideration for the acquisition includes $81.25 million paid predominantly in Tempus common stock, along with Tempus assuming Paige's remaining commitment under its existing Microsoft Azure cloud services agreement [1].Paige.AI is an AI company specializing in digital pathology, with a strong foundation rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated [3]. The acquisition will allow Tempus to expand its dataset, enhance its technical team, and establish a robust presence in digital pathology with an industry-leading technology portfolio [3].
Tempus AI, Inc. is a technology company that leverages artificial intelligence to advance precision medicine. With one of the world's largest libraries of multimodal data and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians, facilitating personalized patient care and advancing drug discovery and development [3].
The acquisition of Paige.AI is expected to accelerate Tempus' efforts in building a large foundation model in oncology, leveraging Paige's de-identified data and AI applications to enhance Tempus' existing products [3]. Tempus' CEO, Eric Lefkofsky, stated that the acquisition of Paige will be catalytic across all of Tempus' AI efforts [3].
Razik Yousfi, CEO and CTO of Paige, expressed confidence in the partnership, stating that the combined forces of Tempus and Paige are uniquely positioned to maximize and expand the reach of their technology, ensuring it fulfills their mission of delivering powerful, data-driven insights [3].
Tempus AI's stock has seen a 2% increase following the announcement of the acquisition [2]. The stock's performance and the acquisition's impact on Tempus' financials will be closely monitored by investors and financial professionals.
References:
[1] https://www.marketscreener.com/news/tempus-ai-inc-acquired-paige-ai-inc-in-a-transaction-valued-at-81-2-million-ce7c50dbd88df121
[2] https://seekingalpha.com/news/4488345-tempus-ai-will-acquire-paige-for-8125m
[3] https://www.businesswire.com/news/home/20250822422844/en/Tempus-Announces-the-Acquisition-of-Paige

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios